Protagonist Therapeutics Stock Performance
| PTGX Stock | USD 25.70 1.15 4.28% |
Protagonist Therapeutics has a performance score of 2 on a scale of 0 to 100. The company holds a Beta of 2.92, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Protagonist Therapeutics will likely underperform. Protagonist Therapeutics right now holds a risk of 3.28%. Please check Protagonist Therapeutics potential upside, as well as the relationship between the accumulation distribution and price action indicator , to decide if Protagonist Therapeutics will be following its historical price patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Protagonist Therapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating technical and fundamental indicators, Protagonist Therapeutics may actually be approaching a critical reversion point that can send shares even higher in May 2024. ...more
Actual Historical Performance (%)
One Day Return (3.68) | Five Day Return (1.41) | Year To Date Return 5.7 | Ten Year Return 111.58 | All Time Return 111.58 |
1 | Payment of 3717 shares by Dinesh Patel of Protagonist Therapeutics subject to Rule 16b-3 | 02/20/2024 |
2 | Were Not Worried About Protagonist Therapeutics Cash Burn | 02/29/2024 |
3 | 4 Must-Buy Stocks for Remarkable Earnings Acceleration | 03/04/2024 |
4 | Disposition of 6490 shares by Harold Selick of Protagonist Therapeutics at 1.89 subject to Rule 16b-3 | 03/07/2024 |
5 | Protagonist Therapeutics, Inc. Shares Bought by Walleye Capital LLC - Defense World | 03/18/2024 |
6 | Protagonist Therapeutics Inc CEO Sells 25,000 Shares - Yahoo Finance | 04/02/2024 |
7 | All You Need to Know About Protagonist Therapeutics Rating Upgrade to Buy | 04/05/2024 |
8 | Disposition of 1234 shares by Asif Ali of Protagonist Therapeutics at 25.11 subject to Rule 16b-3 | 04/18/2024 |
| Begin Period Cash Flow | 126 M |
Protagonist |
Protagonist Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,493 in Protagonist Therapeutics on January 26, 2024 and sell it today you would earn a total of 77.00 from holding Protagonist Therapeutics or generate 3.09% return on investment over 90 days. Protagonist Therapeutics is currently generating 0.1009% in daily expected returns and assumes 3.2841% risk (volatility on return distribution) over the 90 days horizon. In different words, 29% of stocks are less volatile than Protagonist, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Protagonist Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Protagonist Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Protagonist Therapeutics, and traders can use it to determine the average amount a Protagonist Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0307
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | PTGX | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.28 actual daily | 29 71% of assets are more volatile |
Expected Return
| 0.1 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Protagonist Therapeutics is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Protagonist Therapeutics by adding it to a well-diversified portfolio.
Protagonist Therapeutics Fundamentals Growth
Protagonist Stock prices reflect investors' perceptions of the future prospects and financial health of Protagonist Therapeutics, and Protagonist Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Protagonist Stock performance.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (1.32) % | ||||
| Operating Margin | 0.38 % | ||||
| Current Valuation | 1.16 B | ||||
| Shares Outstanding | 58.27 M | ||||
| Price To Earning | (4.81) X | ||||
| Price To Book | 4.68 X | ||||
| Price To Sales | 26.26 X | ||||
| Revenue | 60 M | ||||
| Gross Profit | 26.58 M | ||||
| EBITDA | (90.34 M) | ||||
| Net Income | (78.95 M) | ||||
| Cash And Equivalents | 291.89 M | ||||
| Cash Per Share | 5.95 X | ||||
| Total Debt | 1.14 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 7.59 X | ||||
| Book Value Per Share | 5.83 X | ||||
| Cash Flow From Operations | (70.24 M) | ||||
| Earnings Per Share | (1.39) X | ||||
| Market Capitalization | 1.45 B | ||||
| Total Asset | 357.95 M | ||||
| Retained Earnings | (615.71 M) | ||||
| Working Capital | 334.3 M | ||||
| Current Asset | 83.24 M | ||||
| Current Liabilities | 6.43 M | ||||
About Protagonist Therapeutics Performance
To evaluate Protagonist Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Protagonist Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Protagonist Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Protagonist Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Protagonist's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -1.1 K | -1.1 K | |
| Return On Tangible Assets | (0.22) | (0.23) | |
| Return On Capital Employed | (0.28) | (0.29) | |
| Return On Assets | (0.22) | (0.23) | |
| Return On Equity | (0.23) | (0.22) |
Things to note about Protagonist Therapeutics performance evaluation
Checking the ongoing alerts about Protagonist Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Protagonist Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Protagonist Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 60 M. Net Loss for the year was (78.95 M) with profit before overhead, payroll, taxes, and interest of 26.58 M. | |
| Protagonist Therapeutics currently holds about 291.89 M in cash with (70.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.95. | |
| Protagonist Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 1234 shares by Asif Ali of Protagonist Therapeutics at 25.11 subject to Rule 16b-3 |
- Analyzing Protagonist Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Protagonist Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Protagonist Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Protagonist Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Protagonist Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Protagonist Therapeutics' stock. These opinions can provide insight into Protagonist Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagonist Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.Note that the Protagonist Therapeutics information on this page should be used as a complementary analysis to other Protagonist Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for Protagonist Stock analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is Protagonist Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protagonist Therapeutics. If investors know Protagonist will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protagonist Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.39) | Revenue Per Share 1.057 | Quarterly Revenue Growth (1.00) | Return On Assets (0.19) | Return On Equity (0.29) |
The market value of Protagonist Therapeutics is measured differently than its book value, which is the value of Protagonist that is recorded on the company's balance sheet. Investors also form their own opinion of Protagonist Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protagonist Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protagonist Therapeutics' market value can be influenced by many factors that don't directly affect Protagonist Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protagonist Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protagonist Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protagonist Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.